Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.
1. Recurrence-free survival was significantly different between the adjuvant everolimus and placebo groups. 2. Grade 3 or higher adverse events were more frequent in the everolimus group with oral mucositis being the most reported within this treatment arm. Evidence Rating Level: 1 (Excellent) Study Rundown: Patients with renal cell carcinoma face a high risk of
Merck (MRK) announced topline results from LITESPARK-005, a Phase 3 trial investigating WELIREG, Merck's oral hypoxia-inducible factor-2 alpha inhibitor, in certain previously treated patients with Advanced Renal Cell Carcinoma.